BTIG raises Tempus AI stock price target to $85 on strong Q2 growth

Tempus AI (TEM) reported a robust second quarter, exceeding revenue estimates by 9% with total revenue of $314.6 million, driven by 59.84% overall growth and strong performances in data and core genomics revenue. The company also posted a narrower-than-expected loss per share and subsequently raised its fiscal year 2025 revenue guidance by $10 million. Analysts reacted positively, with BTIG raising its price target to $85 and TD Cowen to $72, citing strong fundamentals and a significant $200 million data deal with AstraZeneca, underscoring the healthcare technology firm's impressive 116.47% year-to-date stock return.

Analysis

Tempus AI (TEM) reported a robust second quarter, significantly outperforming market expectations with revenue of $314.6 million, a 9% beat against the $297.8 million forecast. This top-line strength was driven by impressive year-over-year growth across its key segments, including a 59.84% increase in overall revenue, 36% in data revenue, and 33% in core genomics revenue. The company also demonstrated operational leverage by reporting a narrower-than-anticipated loss per share of -$0.22 versus a projected -$0.25. In response to this performance, management raised its fiscal year 2025 revenue guidance by $10 million. Analyst sentiment is largely positive, with BTIG and TD Cowen raising their price targets to $85 and $72, respectively. BTIG notably characterized the updated guidance as 'conservative,' citing the future impact of a substantial $200 million data deal with AstraZeneca that is expected to bolster revenue in the latter half of 2025. This positive operational news builds on the stock's significant momentum, which has seen a 116.47% year-to-date return. However, a 'Hold' rating from Stifel with a $65 price target indicates that analyst conviction is not universally bullish, providing a point of caution amid the overwhelmingly positive data.

Key Decisions for Investors

• Given the strong earnings beat, raised guidance, and bullish analyst revisions, investors may view these results as a validation of the company's growth trajectory and execution capabilities.
• The $200 million AstraZeneca data deal is a critical future catalyst; investors should monitor management commentary on its integration and revenue contribution in the second half of fiscal 2025.
• Despite the positive news, investors should note the stock's 116.47% year-to-date appreciation and the presence of a 'Hold' rating from Stifel, suggesting that risk associated with its high valuation should be carefully considered.